medRxiv · Nov 16, 2026
Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study
By Amrapala A, Hemrungrojn S, Nupairoj N et al.
Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45 with MBI with or without MCI. We measured ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, and ApoJ, five lipids, and APOE genotype, and computed an atherogenic Apo composite (ApoB-ApoC1-ApoC3). Primary analyses used multivariable linear regression of quantitative cognitive and behavioral outcomes. Group comparisons were secondary and served to contextualize the dimensional regression findings. Results Across Montreal Cognitive Assessment (MoCA) models, 20.7-28.2% of variance was explained by combinations of ApoH, ApoC3, APOE {varepsilon}4 carrier status, age, and male sex (inverse associations), and free cholesterol and education (positive associations). The atherogenic composite was inversely associated with MoCA total, memory index, and delayed recall scores, and with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal fluency and word list recall. No significant predictors emerged for Neuropsychiatric Inventory (NPI) scores or NPI caregiver distress. All nine Apos differed significantly between groups, with levels highest in MCI, intermediate in MBI, and lowest in controls. Conclusions Circulating Apo profiles differed across controls, MCI, and MBI groups and were more consistently associated with cognitive than behavioral outcomes. ApoH and the atherogenic Apo composite warrant further investigation as candidate biomarkers of early cognitive dysfunction.